. 2017 Oct 5;34(10):2210–2231. doi: 10.1007/s12325-017-0610-z

Table 3.

Summary of response rates (investigator-assessed; intent-to-treat population) from SABRINA (follicular lymphoma), MabEase (diffuse large B-cell lymphoma), and SAWYER (chronic lymphocytic leukemia) studies [44, 48]

Study	Treatment group	n	Response rate (%) (95% CI^a)
Study	Treatment group	n	Complete^b	Partial	Overall
SABRINA^c	R(SC) + chemo R(IV) + chemo	205	32 (26–39) 32 (26–39)	52 (45–59) 53 (46–60)	84 (79–89) 85 (79–90)
SABRINA^c	R(SC) + chemo R(IV) + chemo	205	32 (26–39) 32 (26–39)	52 (45–59) 53 (46–60)	84 (79–89) 85 (79–90)
MabEase^c	R(SC) + CHOP R (IV) + CHOP	342	51 (45–56) 42 (35–50)	32 (27–37) 36 (29–43)	82 (78–86) 78 (71–84)
MabEase^c	R(SC) + CHOP R (IV) + CHOP	177	51 (45–56) 42 (35–50)	32 (27–37) 36 (29–43)	82 (78–86) 78 (71–84)
SAWYER Part 2^d	R(SC) + FC R(IV) + FC	88	26 (17–37) 33 (23–44)	59 (48–70) 48 (37–59)	85 (76–92) 81 (71–88)
SAWYER Part 2^d	R(SC) + FC R(IV) + FC	88	26 (17–37) 33 (23–44)	59 (48–70) 48 (37–59)	85 (76–92) 81 (71–88)

CHOP cyclophosphamide, doxorubicin, vincristine, prednisolone, FC fludarabine and cyclophosphamide, IV intravenous, R rituximab, SC subcutaneous

^aWhere available

^bIncludes complete response confirmed and complete response unconfirmed

^cResponse rates at end of induction

^dResponse rates 3 months after treatment completion